LENZ Therapeutics Statistics
Share Statistics
LENZ Therapeutics has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 407 |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 2.07M, so 7.53% of the outstanding shares have been sold short.
| Short Interest | 2.07M |
| Short % of Shares Out | 7.53% |
| Short % of Float | 9.26% |
| Short Ratio (days to cover) | 11.67 |
Valuation Ratios
The PE ratio is -0.81 and the forward PE ratio is -15.85.
| PE Ratio | -0.81 |
| Forward PE | -15.85 |
| PS Ratio | 0 |
| Forward PS | 122.1 |
| PB Ratio | 0.55 |
| P/FCF Ratio | -1 |
| PEG Ratio | n/a |
Enterprise Valuation
LENZ Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 39.2, with a Debt / Equity ratio of 0.
| Current Ratio | 39.2 |
| Quick Ratio | 39.2 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.16 |
| Cash Flow / Debt | -315.81 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | -0.68% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -124.65M |
| Effective Tax Rate | 1 |
Stock Price Statistics
The stock price has increased by 191.08% in the last 52 weeks. The beta is 0, so LENZ Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 191.08% |
| 50-Day Moving Average | 30.84 |
| 200-Day Moving Average | 22.3 |
| Relative Strength Index (RSI) | 42.28 |
| Average Volume (20 Days) | 158.23K |
Income Statement
In the last 12 months, LENZ Therapeutics had revenue of $0 and earned -$124.65M in profits. Earnings per share was $-15.3.
| Revenue | 0 |
| Gross Profit | -2.41M |
| Operating Income | -73.11M |
| Net Income | -124.65M |
| EBITDA | -122.24M |
| EBIT | - |
| Earnings Per Share (EPS) | -15.3 |
Balance Sheet
The company has $185.86M in cash and $362.00K in debt, giving a net cash position of $185.50M.
| Cash & Cash Equivalents | 185.86M |
| Total Debt | 362.00K |
| Net Cash | 185.50M |
| Retained Earnings | -367.05M |
| Total Assets | 224.01M |
| Working Capital | 212.99M |
Cash Flow
In the last 12 months, operating cash flow was -$90.01M and capital expenditures -$10.86M, giving a free cash flow of -$100.86M.
| Operating Cash Flow | -90.01M |
| Capital Expenditures | -10.86M |
| Free Cash Flow | -100.86M |
| FCF Per Share | -12.38 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
LENZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -49.35% |
| FCF Yield | -11.83% |
Analyst Forecast
The average price target for LENZ is $36, which is 16.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $36 |
| Price Target Difference | 16.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 22, 2024. It was a backward split with a ratio of 1:7.
| Last Split Date | Mar 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | 57.5 |
| Piotroski F-Score | 1 |